1. Home
  2. SHC vs EWTX Comparison

SHC vs EWTX Comparison

Compare SHC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sotera Health Company

SHC

Sotera Health Company

SELL

Current Price

$17.91

Market Cap

5.2B

Sector

Health Care

ML Signal

SELL

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

SELL

Current Price

$37.22

Market Cap

4.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SHC
EWTX
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.3B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SHC
EWTX
Price
$17.91
$37.22
Analyst Decision
Buy
Buy
Analyst Count
10
13
Target Price
$22.61
★ $52.62
AVG Volume (30 Days)
★ 1.8M
1.4M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 68.75
N/A
EPS
★ 0.28
N/A
Revenue
★ $1,163,617,000.00
N/A
Revenue This Year
$7.16
N/A
Revenue Next Year
$5.91
N/A
P/E Ratio
$64.59
★ N/A
Revenue Growth
★ 5.74
N/A
52 Week Low
$13.09
$14.68
52 Week High
$19.85
$48.51

Technical Indicators

Market Signals
Indicator
SHC
EWTX
Relative Strength Index (RSI) 42.82 37.07
Support Level $16.74 $30.66
Resistance Level $18.77 $41.22
Average True Range (ATR) 0.49 1.64
MACD -0.03 -0.27
Stochastic Oscillator 24.83 24.19

Price Performance

Historical Comparison
SHC
EWTX

About SHC Sotera Health Company

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: